| 2026 | 5-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuationWang Y, Yao Y, Su R, Yan H · British Journal of Pharmacologydoi:10.1111/bph.70307 | moderate | consumed | 1 section |
| 2026 | In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocinJurowski K, Kobylarz D, Noga M · Archives of Toxicologydoi:10.1007/s00204-026-04365-4 | moderate | consumed | 2 sections |
| 2026 | Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive SubstancesRached G, Campana A, Fiani D, et al. · CNS Drugsdoi:10.1007/s40263-025-01256-7 | strong | consumed | 1 section |
| 2025 | Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc AnalysisOtto ME, van der Heijden KV, Schoones JW, et al. · Clinical Pharmacokineticsdoi:10.1007/s40262-024-01454-4 | strong | consumed | 2 sections |
| 2025 | Elucidating the Phase I metabolism of psilocin in vitroChen J, Wang Z, Yong CY, et al. · Archives of Toxicologydoi:10.1007/s00204-024-03952-7 | moderate | consumed | 3 sections |
| 2025 | Pharmacokinetics of Psilocybin: A Systematic ReviewMeshkat S, Al-Shamali H, Perivolaris A, et al. · Pharmaceuticsdoi:10.3390/pharmaceutics17040411 | strong | consumed | 2 sections |
| 2025 | The polypharmacology of psychedelics reveals multiple targets for potential therapeuticsJain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, Suomivuori CM, Huang XP, Shub L, DiBerto JF, Kim K, DeLeon C, Krumm BE, Fay JF, Keiser M, Hauser AS, Dror RO, Shoichet B, Gloriam DE, Nichols DE, Roth BL · Neurondoi:10.1016/j.neuron.2025.06.012 | strong | consumed | 2 sections |
| 2024 | 4-AcO-DMTWikipedia contributorsurl:946c31199207c835 | weak | consumed | cited only |
| 2024 | In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybinJones NT, Wagner L, Hahn MCP, Scarlett CO, Wenthur CJ · Frontiers in Psychiatrydoi:10.3389/fpsyt.2023.1303365 | strong | consumed | 5 sections |
| 2024 | Rewarding Effects of the Hallucinogen 4-AcO-DMT Administration and Withdrawal in Rats: A Challenge to the Opponent-Process TheoryVargas-Perez H, Minauro-Sanmiguel F, Ting-A-Kee R, Grieder TE, Méndez-Díaz M, Próspero-García O, van der Kooy D · Neuroscience Lettersdoi:10.1016/j.neulet.2023.137597 | strong | consumed | 2 sections |
| 2023 | A non-hallucinogenic LSD analog with therapeutic potential for mood disordersLewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB, Calkins MM, Bautista-Carro MA, Arsenault E, Telfer A, Taghavi-Abkuh FF, Malcolm NJ, El Sayegh F, Abizaid A, Schmid Y, Morton K, Halberstadt AL, Aguilar-Valles A, McCorvy JD · Cell Reportsdoi:10.1016/j.celrep.2023.112203 | strong | consumed | 1 section |
| 2023 | Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial CellsRobinson GI, Li D, Wang B, Zahoruiko Y, Gerasymchuk M, Hudson D, Kovalchuk O, Kovalchuk I · Current Issues in Molecular Biologydoi:10.3390/cimb45080427 | moderate | consumed | cited only |
| 2023 | Psilocin - The 'real deal' or an extraction byproductGutman O, Tenne D, Bretler U · Journal of Forensic Sciencesdoi:10.1111/1556-4029.15167 | moderate | consumed | 1 section |
| 2023 | Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal TissueRobinson GI, Li D, Wang B, Rahman T, Gerasymchuk M, Hudson D, Kovalchuk O, Kovalchuk I · Lifedoi:10.3390/life13122345 | moderate | consumed | 1 section |
| 2023 | Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in MiceGlatfelter GC, Naeem M, Pham DNK, Golen JA, Chadeayne AR, Manke DR, Baumann MH · ACS Pharmacology & Translational Sciencedoi:10.1021/acsptsci.2c00222 | strong | consumed | 5 sections |
| 2022 | Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in MiceGlatfelter GC, Pottie E, Partilla JS, Sherwood AM, et al. · ACS Pharmacology and Translational Sciencedoi:10.1021/acsptsci.2c00177 | moderate | consumed | 5 sections |
| 2022 | Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MSZhai W, Li L, Zhao J, Xiang P, Liu M, Shi Y, Dang Y · Drug Testing and Analysisdoi:10.1002/dta.3255 | strong | consumed | 5 sections |
| 2020 | Designer drugs: mechanism of action and adverse effectsLuethi D, Liechti ME · Archives of Toxicologydoi:10.1007/s00204-020-02693-7 | strong | consumed | 1 section |
| 2020 | Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin ReceptorKim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL · Celldoi:10.1016/j.cell.2020.08.024 | strong | consumed | 1 section |
| 2019 | Bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrugChadeayne AR, Golen JA, Manke DR · Acta Crystallographica Section E Crystallographic Communicationsdoi:10.1107/s2056989019007370 | strong | consumed | 2 sections |
| 2018 | Chemistry and Structure-Activity Relationships of Psychedelics.Nichols DE · Current Topics in Behavioral Neurosciencesdoi:10.1007/7854_2017_475 | strong | consumed | 3 sections |
| 2018 | Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic PerspectivesMartinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, Di Giannantonio M, Gallimberti L · Brain Sciencesdoi:10.3390/brainsci8030047 | moderate | consumed | 1 section |
| 2017 | A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy SubjectsDolder PC, Grünblatt E, Müller F, Borgwardt SJ, Liechti ME · Frontiers in Pharmacologydoi:10.3389/fphar.2017.00423 | strong | consumed | 1 section |
| 2016 | 4-AcO-DMT (Psilacetin) - Erowid BasicsErowidurl:7a90964f24ed4f5d | weak | consumed | cited only |
| 2016 | Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogensRickli A, Moning OD, Hoener MC, Liechti ME · European Neuropsychopharmacologydoi:10.1016/j.euroneuro.2016.05.001 | strong | consumed | 1 section |
| 2005 | Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.Gillman PK · British Journal of Anaesthesiapmid:16051647 | strong | consumed | 1 section |
| 1999 | Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of PsilocinNichols DE, Frescas S · Synthesisdoi:10.1055/s-1999-3490 | moderate | consumed | 3 sections |